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ALT

:   alanine aminotransferase

AST

:   aspartate aminotransferase

BMI

:   body mass index

CAP

:   controlled attenuation parameter

CI

:   confidence interval

CT

:   computed tomography

DMGA

:   dorsal muscle group area

DMGLDA

:   dorsal muscle group low density area

FIB‐4

:   Fibrosis‐4 markers

HbA1c

:   glycosylated hemoglobin

HOMA‐IR

:   homeostasis model assessment of insulin resistance

HU

:   Hounsfield unit

IQR

:   interquartile range

LFS

:   liver fat score

LSM

:   liver stiffness measurement

MS

:   metabolic syndrome

NAFLD

:   nonalcoholic fatty liver disease

NAFLD‐FS

:   NAFLD fibrosis score

NASH

:   nonalcoholic steatohepatitis

SFA

:   subcutaneous fat area

VFA

:   visceral fat area

WC

:   waist circumference

WHO

:   World Health Organization

Nonalcoholic fatty liver disease (NAFLD) comprises a spectrum from minimal to severe steatosis, and from steatosis alone to steatohepatitis (NASH), cirrhosis, and hepatocellular carcinoma (HCC). With the improvement of China\'s economy, there has been a marked increase in the prevalence of NAFLD in China in the last decade. Recent systematic review and meta‐analysis found the prevalence of NAFLD in China was 32.3% (95% confidence interval \[CI\], 30.2‐34.4) in 2015‐2018,[1](#hep41435-bib-0001){ref-type="ref"} with a rapid increase from 25.4% in 2008‐2010[1](#hep41435-bib-0001){ref-type="ref"} and 18.2%‐20% in 2000--2007.[2](#hep41435-bib-0002){ref-type="ref"} The prevalence of NAFLD was 51.6% (95% CI, 47.1‐56.2) in persons with high body mass index (BMI) and 10.8% (95% CI, 9.0‐12.6) in those with normal BMI.[1](#hep41435-bib-0001){ref-type="ref"}

NAFLD is associated with excess fat deposition not only in the liver, but also in the subcutaneous and visceral compartments. Fat can also be deposited in ectopic areas. Many studies have shown that fat in visceral compartment and ectopic sites---notably muscles---plays a more prominent role in the development of NAFLD and metabolic syndrome (MS)[3](#hep41435-bib-0003){ref-type="ref"}, [4](#hep41435-bib-0004){ref-type="ref"}, [5](#hep41435-bib-0005){ref-type="ref"} as well as cancers[6](#hep41435-bib-0006){ref-type="ref"} than fat in the subcutaneous tissues. Studies in Japan and Korea found that visceral fat and intramuscular adipose tissue was associated with hepatic fibrosis and NASH in patients with NAFLD.[7](#hep41435-bib-0007){ref-type="ref"}, [8](#hep41435-bib-0008){ref-type="ref"}, [9](#hep41435-bib-0009){ref-type="ref"}

Historically, steatosis alone was considered to be benign and not associated with progressive liver damage, and patients with steatosis alone have life expectancy similar to the normal population.[10](#hep41435-bib-0010){ref-type="ref"}, [11](#hep41435-bib-0011){ref-type="ref"} Recent studies indicate that patients with steatosis alone may develop steatohepatitis and progressive liver damage.[12](#hep41435-bib-0012){ref-type="ref"}, [13](#hep41435-bib-0013){ref-type="ref"} Several new drugs in development for NAFLD aim at decreasing the amount of fat in the liver[14](#hep41435-bib-0014){ref-type="ref"}, [15](#hep41435-bib-0015){ref-type="ref"}; however, there are limited data comparing metabolic abnormalities and liver disease between patients with moderate to severe steatosis and those with mild steatosis. There are also very few studies correlating fat in the liver with fat deposition in other body compartments. Therefore, the aims of this study were (1) to measure the quantity and quality of fat in subcutaneous, visceral and muscle compartments in Chinese patients with NAFLD and to correlate fat in these compartments with the degree of hepatic steatosis, and (2) to compare liver damage and the prevalence of metabolic abnormalities between Chinese patients with NAFLD and moderate to severe hepatic steatosis versus those with mild steatosis.

Patients and Methods {#hep41435-sec-0002}
====================

Study Subjects {#hep41435-sec-0003}
--------------

Adult patients aged 18 years or older with NAFLD were prospectively recruited from Peking University People\'s Hospital in Beijing, China. Diagnosis of NAFLD was based on ultrasound, computed tomography (CT), or magnetic resonance imaging within 24 months or liver biopsy within 36 months of enrollment. Patients with other causes of liver disease such as hepatitis B, hepatitis C, alcohol (\> 14 drinks/week for men and \>7 drinks/week for women during the past year), and other causes of hepatic steatosis (e.g., medications such as tamoxifen and corticosteroids) were excluded.[10](#hep41435-bib-0010){ref-type="ref"}, [16](#hep41435-bib-0016){ref-type="ref"} Also excluded were patients who had a history of or plans to undergo bariatric surgery or endoscopic procedures for weight reduction or history of liposuction, patients who were taking medications or supplements for weight reduction, patients who experienced significant weight loss over 5% within 24 months prior to enrollment, patients who had hepatic decompensation or HCC, and women who were pregnant. This pilot study had a planned enrollment of equal number of patients with normal BMI (\< 24 kg/m^2^) and BMI in the obesity range (≥ 28 kg/m^2^), based on cutoffs recommended for Chinese adults.[17](#hep41435-bib-0017){ref-type="ref"} The study was approved by the institutional review boards of Peking University and the University of Michigan.

Potentially eligible patients were identified and approached in the clinic. Patients who agreed to participate were screened after providing written informed consent. During the screening visit, demographics (sex, age, race/ethnicity, occupation, and education levels), anthropometrics (height and weight), medical history, current medications, and alcohol history were recorded. Patients confirmed to meet the eligibility criteria were scheduled to return for a baseline visit after overnight fasting for at least 8 hours. During the baseline visit, family history and obesity history were recorded, and weight, waist circumference (WC), hip circumference, and blood pressure were measured. Truncal obesity was defined as WC of 90 cm or more for males and 85 cm or more for females.[17](#hep41435-bib-0017){ref-type="ref"} Blood was collected for glycosylated hemoglobin (HbA1c), insulin, glucose, lipids, blood count, uric acid, liver panel, and hepatitis B surface antigen and hepatitis C antibody if not previously documented to be negative. All patients underwent vibration‐controlled transient elastography (FibroScan®; EchoSens, Paris, France) and an abbreviated noncontrast single‐phase CT that included only the upper abdomen spanning the T11‐L3 vertebra.

Measurements of Hepatic Steatosis and Definition of Moderate/Severe Hepatic Steatosis {#hep41435-sec-0004}
-------------------------------------------------------------------------------------

Hepatic steatosis was determined by CT, and moderate/severe hepatic steatosis was defined as CT liver attenuation of 40 or fewer Hounsfield units (HU).[18](#hep41435-bib-0018){ref-type="ref"}, [19](#hep41435-bib-0019){ref-type="ref"}, [20](#hep41435-bib-0020){ref-type="ref"} The ratio of liver/spleen HU, FibroScan® controlled attenuation parameter (CAP), and NAFLD liver fat score (LFS) was also examined to assess the degree of hepatic steatosis, and the results were correlated with CT liver attenuation.

Measurements of Liver Fibrosis {#hep41435-sec-0005}
------------------------------

Liver fibrosis was assessed by transient elastography, NAFLD fibrosis score (NAFLD‐FS) and Fibrosis‐4 markers (FIB‐4). Liver stiffness measurement (LSM) was performed using FibroScan. All operators had performed at least 100 examinations before this study and were blinded to the clinical data of the participants. An XL probe was used for obese patients. LSM was considered reliable if 10 valid measurements with an interquartile range (IQR)/median ratio of less than 30% and a success rate of over 60% were obtained. A cut‐off value of 10.1 kPa was used to define advanced fibrosis of F3 or higher.[21](#hep41435-bib-0021){ref-type="ref"} NAFLD‐FS[22](#hep41435-bib-0022){ref-type="ref"} and FIB‐4[23](#hep41435-bib-0023){ref-type="ref"} were calculated using the previously published formula.

Measurements of Subcutaneous, Visceral, and Intermuscular Fat {#hep41435-sec-0006}
-------------------------------------------------------------

All patients underwent a limited noncontrast CT, and body composition was measured using Analytic Morphomics.[24](#hep41435-bib-0024){ref-type="ref"}, [25](#hep41435-bib-0025){ref-type="ref"}, [26](#hep41435-bib-0026){ref-type="ref"}, [27](#hep41435-bib-0027){ref-type="ref"}, [28](#hep41435-bib-0028){ref-type="ref"} Analytic morphomics is a platform of semi‐automatic image analysis software developed at the University of Michigan. It is able to anatomically index CT scan data so that each measurement is precise and reproducible. Briefly, coded de‐identified Digital Imaging and Communications in Medicine files of all CT scans were loaded into the analytic morphomics server. A semi‐automated high‐throughput methodology with algorithms programmed in MATLAB® (MathWorks Inc., Natick, MA) was used for image processing and analysis. All imaging studies were first anatomically indexed using semi‐automated identification of spinal vertebral levels to allow for accurate and standardized measurements of the same area in each patient. All geometries were saved in a stereolithography format in the analytic morphomics database, with PostgresSQL (<https://www.postgresql.org/>) subsequently retrieved to calculate geometric (linear distances or cross‐sectional areas) and HU measurements with customized algorithms. Descriptions of all analytic morphomic measurements used for this study can be found in the data dictionary (<http://www.med.umich.edu/surgery/morphomics/data_dictionary>).

The visceral fat area (VFA) was defined as the total area inside the abdominal fascia, and subcutaneous fat area (SFA) as the total area between the abdominal fascia and skin, meeting fat density thresholds (−205 to −51 HU).[26](#hep41435-bib-0026){ref-type="ref"} The dorsal muscle group area (DMGA) was defined as the cross‐sectional area of pixels within a triangle boundary between the spinal canal and the left and right lateral seams, connected by the nearest location to the posterior fascia envelope.[28](#hep41435-bib-0028){ref-type="ref"} Fat areas were measured at T12, L1, and L2 and compared.

The morphomic measures considered in this analysis included VFA, SFA, DMGA, and dorsal muscle group low‐density area (DMGLDA), reflecting the intermuscular fat, dorsal muscle group normal density area, visceral fat HU, subcutaneous fat HU, and dorsal muscle group HU. We also determined the ratio of visceral to subcutaneous fat area, visceral and subcutaneous fat areas to BMI, and intermuscular fat to total dorsal muscle group area: DMGLDA to DMGA.

Definition of Metabolic Abnormalities {#hep41435-sec-0007}
-------------------------------------

MS was defined based on the joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention, which required participants to meet three of five criteria: truncal obesity, hypertension, diabetes or hyperglycemia, hypertriglyceridemia, and low value for high density lipoprotein.[29](#hep41435-bib-0029){ref-type="ref"} The diagnosis of diabetes mellitus was based on the World Health Organization (WHO) 1999 criteria[30](#hep41435-bib-0030){ref-type="ref"} and the Chinese Diabetes Society 2013 guidelines[31](#hep41435-bib-0031){ref-type="ref"}: fasting plasma glucose of 7.0 mmol/L or higher or HbA1c of 6.5% or higher, previously diagnosed type 2 diabetes, or currently on medications for elevated glucose.

Insulin sensitivity was determined by the homeostasis model assessment of insulin resistance (HOMA‐IR),[32](#hep41435-bib-0032){ref-type="ref"} and a cutoff of greater than 2.0 previously used to define a healthy population was used to define insulin resistance.[33](#hep41435-bib-0033){ref-type="ref"}

Measurements of Diet and Physical Activity {#hep41435-sec-0008}
------------------------------------------

Calorie intake and physical activity were based on self‐report during in‐person and telephone interviews. We collected physical activity data using the Global Physical Activity Questionnaire (GPAQ) developed by WHO.[34](#hep41435-bib-0034){ref-type="ref"} It had been tested in large‐scale population‐based surveys and is available in English and Chinese. It collects information on physical activity participation in three domains: activities at work, transport‐related activities (travel to and from places), and recreational activities. WHO recommends that adults do at least 150 minutes of moderate‐intensity physical activity *or* 75 minutes of vigorous‐intensity physical *activity or* a combination of moderate‐intensity and vigorous‐intensity physical activity that achieves at least 600 metabolic equivalent--minutes each week. Physical activity data were analyzed based on the GPAQ Analysis Guide.[35](#hep41435-bib-0035){ref-type="ref"}

Diet was assessed based on food recall and calorie intake estimated using a software based on the Standard Tables of Food Composition in China.[36](#hep41435-bib-0036){ref-type="ref"}, [37](#hep41435-bib-0037){ref-type="ref"} All food and beverages taken in the previous day were recorded on three occasions: at screening visit, at baseline visit, and during a phone visit between the screening and baseline visit that was selected by the investigators. The 3 days in which information on diet was recorded included 2 weekdays and 1 Saturday or Sunday, with avoidance of major holidays or festivals. Diet information was converted into calories.

Statistical Analyses {#hep41435-sec-0009}
--------------------

Statistical analyses were performed using SPSS version 25 (Chicago, IL). Continuous variables were expressed as median values (IQR), and comparisons made using unpaired Student *t* test if the variables were normally distributed and Mann‐Whitney U test if the variables were not normally distributed. Categorical data were described as proportions and compared using the chi‐square test. All provided *P* values represent the results of two‐sided tests, and *P* values less than 0.05 were considered statistically significant.

Bivariate associations between variables of interest were assessed by Pearson\'s correlation coefficients and Spearman\'s correlation coefficients when variables were not normally distributed. Fat and muscle areas at T12, L1, and L2 levels were compared and were highly correlated (*r* \> 0.8); thus, all results presented were assessed at L2 level.

Results {#hep41435-sec-0010}
=======

Characteristics of the Patients Studied {#hep41435-sec-0011}
---------------------------------------

From May 2016 to August 2018, 169 NAFLD patients were recruited. Among them, 160 completed CT scans and were included in this analysis. Median age was 46.5 years (IQR 35.3‐58.0), 45.6% were men, and all were Han Chinese. More than half of the patients (68.1%) had some college education, and 58.8% were white‐collar workers. Median BMI was 26.0 kg/m^2^ (IQR 23.1‐30.4), and 80 (50%) patients had normal BMI. A total of 90 (56.3%) patients had MS, 61 (38.1%) had hyperglycemia, and 70 (43.8%) had hypertension based on medical history, current medications, or laboratory results at the baseline visit (Table [1](#hep41435-tbl-0001){ref-type="table"}). Only 5 patients had a liver biopsy, of whom 4 had NASH.

###### 

Clinical Characteristics of Chinese NAFLD Patients With Moderate/Severe Versus Mild Hepatic Steatosis

  Characteristics                                                        All                    Moderate/Severe Hepatic Steatosis (Liver HU** ≤ **40)   Mild Hepatic Steatosis (Liver HU \> 40)   *P* Value
  ---------------------------------------------------------------------- ---------------------- ------------------------------------------------------- ----------------------------------------- -------------
  N                                                                      160                    53                                                      107                                       
  Male sex                                                               73 (45.6%)             26 (49.1%)                                              47 (43.9%)                                0.540
  Age (years)                                                            46.5 (35.3, 58)        46 (33.5, 57.5)                                         48 (37, 58)                               0.449
  BMI (kg/m^2^)                                                          26 (23.1, 30.4)        29.1 (23.9, 31.5)                                       23.8 (22.5, 30.2)                         **0.002**
  Normal BMI                                                             80 (50%)               19 (35.8%)                                              61 (57%)                                  **0.012**
  Waist circumference (cm)                                               87 (80, 97)            93 (83, 102)                                            84 (78.5, 94)                             **0.001**
  AST, U/L                                                               27 (21, 36.8)          34 (25, 42.5)                                           25 (19, 33)                               **\<0.001**
  ALT, U/L                                                               33 (22.3, 47.8)        43 (30.5, 63)                                           27 (19, 39)                               **\<0.001**
  Medical History                                                                                                                                                                                 
  Diabetes                                                               22 (13.8%)             9 (17%)                                                 13 (12.1%)                                0.404
  Hypertension                                                           36 (22.5%)             14 (26.4%)                                              22 (20.6%)                                0.404
  Dyslipidemia                                                           84 (52.5%)             35(66%)                                                 49 (45.8%)                                **0.037**
  Metabolic Abnormalities                                                                                                                                                                         
  HbA1c (%)                                                              5.8 (5.6, 6.3)         5.9 (5.7, 6.6)                                          5.8 (5.6, 6.2)                            **0.039**
  HOMA‐IR                                                                3.8 (2.6, 5.6)         5.3 (3.2, 7.9)                                          3.3 (2.4, 4.7)                            **\<0.001**
  HOMA‐IR_non‐DM[\*](#hep41435-note-0004){ref-type="fn"}                 3.6 (2.5, 5.2)         4.7 (3.1, 7.1)                                          3.2 (2.4, 4.6)                            **0.001**
  Triglyceride (mmol/L)                                                  2.1 (1.4, 2.6)         2.3 (1.5, 3.6)                                          1.9 (1.4, 2.5)                            **0.011**
  Triglyceride_non‐LIP[†](#hep41435-note-0005){ref-type="fn"} (mmol/L)   2.1 (1.4, 2.6)         2.2 (1.6, 3.7)                                          1.8 (1.4, 2.5)                            **0.027**
  Fasting glucose (mmol/L)                                               5.4 (5, 6.1)           5.6 (5.1, 6.8)                                          5.3 (4.9, 5.9)                            **0.010**
  Metabolic Syndrome                                                     90 (56.3%)             38 (71.7%)                                              52 (48.6%)                                **0.006**
  Truncal obesity                                                        97 (60.6%)             38 (71.7%)                                              59 (55.1%)                                **0.044**
  Hypertension                                                           70 (43.8%)             30 (56.6%)                                              40 (37.4%)                                **0.021**
  Hyperglycemia                                                          61 (38.1%)             24 (45.3%)                                              37 (34.6%)                                0.190
  Hypertriglyceridemia                                                   108 (67.5%)            42 (79.2%)                                              66 (61.7%)                                **0.026**
  Low HDL                                                                94 (58.8%)             32 (60.4%)                                              62 (57.9%)                                0.769
  Hepatic Steatosis                                                                                                                                                                               
  CT scan                                                                                                                                                                                         
  Liver HU                                                               47.3 (36.4, 54.4)      30.4 (23.8, 36.5)                                       51.3 (47, 57)                             **\<0.001**
  Liver/spleen HU ratio                                                  0.98 (0.78, 1.13)      0.63 (0.5, 0.79)                                        1.08 (0.98, 1.18)                         **\<0.001**
  FibroScan CAP (dB/m)                                                   297.5 (250.5, 332.8)   334 (311.5, 367.5)                                      272 (235, 310)                            **\<0.001**
  LFS                                                                    0.7 (−0.9, 2.3)        2.3 (0.4, 3.8)                                          0.2 (−1.1, 1.5)                           **\<0.001**
  Hepatic Fibrosis                                                                                                                                                                                
  FibroScan LSM (kPa)                                                    4.5 (3.7, 5.3)         4.8 (4, 5.7)                                            4.4 (3.6, 5.2)                            **0.036**
  NAFLD‐FS                                                               (−2.5) (−3.4, −1.5)    (−2.7) (−3.4, −1.6)                                     (−2.4) (−3.4, −1.4)                       0.513
  FIB‐4                                                                  0.9 (0.7, 1.3)         0.9 (0.6, 1.2)                                          1.0 (0.7, 1.4)                            0.245

Data are expressed as median (IQR) or n (%). Bold values have *P* Values \<0.05.

Non‐DM: Patients who were not on diabetic medication.

Non_LIP: Patients who were not on lipid‐lowering medications.

Abbreviations: DM, diabetes mellitus; HDL, high density lipoprotein; LIP, lipid‐lowering medications.
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Hepatic Steatosis and Liver Fibrosis {#hep41435-sec-0012}
------------------------------------

Fifty‐three patients (33.1%) had moderate/severe hepatic steatosis (liver HU** ≤ **40), including 19 (35.8%) with normal BMI, and 107 patients (66.9%) had mild hepatic steatosis, including 61 (57%) with normal BMI. Compared to patients with mild hepatic steatosis, patients with moderate/severe hepatic steatosis had higher CAP and LFS, and lower liver/spleen HU ratio (*P* \< 0.001) (Table [1](#hep41435-tbl-0001){ref-type="table"}). There was a strong negative correlation between liver HU and CAP (Fig. [1](#hep41435-fig-0001){ref-type="fig"}, *r* = −0.663, *P* \< 0.001).

![Correlation between hepatic steatosis measured by liver HU on CT scan and CAP on FibroScan. Scatter plot shows a strong negative correlation between liver HU and CAP in Chinese patients with NAFLD (*r* = −0.663, *P* \< 0.001).](HEP4-3-1585-g001){#hep41435-fig-0001}

Patients with moderate/severe hepatic steatosis had higher BMI and WC (Table [1](#hep41435-tbl-0001){ref-type="table"} and Fig. [2](#hep41435-fig-0002){ref-type="fig"}A), and liver HU showed a weak negative correlation with BMI (*r* = −0.362, *P* \< 0.001) and a moderate negative correlation with WC (*r* = −0.411, *P* \< 0.001) (Fig. [2](#hep41435-fig-0002){ref-type="fig"}B).

![Waist circumference and hepatic steatosis. (A) Box plot shows WC in patients with moderate/severe steatosis versus mild hepatic steatosis. Overall cohort: 93 (83‐102) versus 84 (78.5‐94.0) cm (*P* = 0.001); male: 98 (87.0‐106.3) versus 87 (81‐98) cm (*P* \< 0.05); female: 89 (83‐98) versus 83 (77‐90.8) cm (*P* \< 0.05). Boxes show 25th and 75th percentiles; horizontal line shows median; and cross (x) shows mean value. (B) Scatter plot shows a moderate negative correlation between hepatic steatosis measured by liver HU on CT scan and WC in Chinese patients with NAFLD (*r* = −0.411, *P* \< 0.001).](HEP4-3-1585-g002){#hep41435-fig-0002}

Patients with moderate/severe hepatic steatosis had more liver damage, as reflected by higher aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels, as well as higher LSM (4.8 kPa vs. 4.4 kPa) than those with mild steatosis, but there were no significant differences in NAFLD‐FS or FIB‐4 scores between the two groups (Table [1](#hep41435-tbl-0001){ref-type="table"}).

Correlation Between Hepatic Steatosis and Fat in Visceral, Subcutaneous, and Muscle Compartments {#hep41435-sec-0013}
------------------------------------------------------------------------------------------------

Hepatic steatosis measured by liver HU showed a moderate correlation with fat in visceral compartment, and a weak correlation with fat in subcutaneous and muscle compartments (Fig. [3](#hep41435-fig-0003){ref-type="fig"}A‐C). Compared to patients with mild hepatic steatosis, patients who had moderate/severe hepatic steatosis had larger VFA and SFA (Fig. [4](#hep41435-fig-0004){ref-type="fig"}A,B), but after adjustment for BMI, only the ratio of VFA to BMI, but not SFA to BMI, was significantly higher. Patients with moderate/severe hepatic steatosis also had a higher ratio of VFA to SFA than those with mild steatosis, but this difference was not significant. Given the possible negative consequences associated with visceral fat density,[38](#hep41435-bib-0038){ref-type="ref"} we also examined this and found that patients with moderate/severe hepatic steatosis had lower visceral fat density (visceral fat HU) than those with mild steatosis, but there was no difference in subcutaneous fat density (Table [2](#hep41435-tbl-0002){ref-type="table"}). Patients who had moderate/severe hepatic steatosis also had bigger DMGA and DMGLDA but there were no differences in density of dorsal muscles (DMG HU) or the relative amount of low‐density muscle as compared with total muscle (DMGLDA to DMGA) (Fig. [4](#hep41435-fig-0004){ref-type="fig"}C and Table [2](#hep41435-tbl-0002){ref-type="table"}).

![Scatter plots show correlation between hepatic steatosis measured by liver HU and VFA (A), SFA (B), and DMGLDA (C) on CT scan.](HEP4-3-1585-g003){#hep41435-fig-0003}

![Box plots show VFA (A), SFA (B), and DMGLDA (C) in patients with moderate/severe versus mild hepatic steatosis, overall and separately for men and women. (A) Median (IQR) areas (cm^2^) of VFA in patients with moderate/severe versus mild hepatic steatosis. Overall cohort: 177.6 (143.5‐227.9) versus 134.8 (108.4‐191.8) (*P* \< 0.001); male: 209.9 (176.7‐283.4) versus 159.8 (111.9‐223.4) (*P* \< 0.01); female: 155.6 (132.1‐197.4) versus 129.3 (104.7‐174.8) (*P* \< 0.05). (B) SFA in patients with moderate/severe versus mild hepatic steatosis. Overall cohort: 161.4 (114.3‐230.0) versus 138.6 (98.9‐207.2) (*P* \< 0.05); male: 150.7 (92.1‐212.7) versus 98.9 (73.6‐189.2) (*P* = 0.06); female: 188.2 (135.8‐241.5) versus 152.7 (127.5‐214.7) (*P* = 0.119). (C) DMGLDA in patients with moderate/severe versus mild hepatic steatosis. Overall cohort: 10.5 (7.9‐12.1) versus 8.9 (7.1‐10.8) (*P* \< 0.05); male: 10.7 (8.1‐13.1) versus 9.4 (7.3‐12) (*P* = 0.211); female: 10.5 (7.6‐11.5) versus 8.48 (6.9‐10) (*P* = 0.172). Boxes show 25th and 75th percentiles; horizontal line shows median; and cross (x) shows mean value.](HEP4-3-1585-g004){#hep41435-fig-0004}

###### 

Visceral, Subcutaneous, and Muscle Fat Measurements in Chinese NAFLD Patients With Moderate/Severe Versus Mild Hepatic Steatosis

  Characteristics          All                    Moderate/Severe Hepatic Steatosis (Liver HU** ≤ **40)   Mild Hepatic Steatosis (Liver HU \> 40)   *P* Value
  ------------------------ ---------------------- ------------------------------------------------------- ----------------------------------------- -------------
  VFA (cm^2^)              155.4 (117.9, 207.7)   177.6 (143.5, 227.9)                                    134.8 (108.44, 191.8)                     **\<0.001**
  Visceral fat HU          (−107) (−109, −105)    (−109) (−110.8, −106)                                   (−107) (−109, −104)                       **\<0.001**
  SFA (cm^2^)              143.9 (103.7, 216.1)   161.4 (114.3, 230)                                      138.6 (98.9, 207.2)                       **0.035**
  Subcutaneous fat HU      (−112) (−114, −109)    (−112) (−114, −108)                                     (−112) (−114, −109)                       0.807
  VFA‐to‐BMI ratio         5.9 (4.6, 7.7)         6.7 (5.4, 8)                                            5.5 (4.3, 7.4)                            **0.003**
  SFA‐to‐BMI ratio         5.8 (4.3, 7.4)         6.1 (4.6, 7.6)                                          5.5(4.1, 7.3)                             0.186
  VFA‐to‐SFA ratio         1.0 (0.8, 1.4)         1.2 (0.8, 1.5)                                          1.0 (0.8, 1.4)                            0.258
  DMGA (cm^2^)             47.0 (37.2, 56)        50.2 (40.2, 61.2)                                       44.4 (35.7, 53.8)                         **0.010**
  DMGLDA (cm^2^)           9.3 (7.3, 11.4)        10.5 (7.9, 12.1)                                        8.9 (7.1, 10.8)                           **0.025**
  Dorsal muscle group HU   48.2 (42.1, 52.3)      47.2 (42.1, 51.5)                                       48.6 (42.16, 52.7)                        0.615
  DMGLDA‐to‐DMGA ratio     0.2 (0.17, 0.25)       0.21 (0.17, 0.24)                                       0.2 (0.17, 0.25)                          0.945

Data are expressed as median (IQR). Bold values have *P* Values \<0.05.
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Correlations Between Hepatic Steatosis and Metabolic Abnormalities {#hep41435-sec-0014}
------------------------------------------------------------------

Patients with moderate/severe hepatic steatosis had a higher prevalence of dyslipidemia by medical history and MS than those with mild steatosis (Table [1](#hep41435-tbl-0001){ref-type="table"}). They also had higher levels of HbA1c, HOMA‐IR, triglyceride, and fasting plasma glucose, but there were no differences in prevalence of diabetes.

Diet and Physical Activity {#hep41435-sec-0015}
--------------------------

Median total calorie intake per day was 1,527 kcal (IQR 1,237‐1,911) and was significantly higher in patients with moderate/severe hepatic steatosis (1,633 kcal vs. 1,456 kcal) than those with mild steatosis (Table [3](#hep41435-tbl-0003){ref-type="table"}). Patients with moderate/severe hepatic steatosis had higher intake of carbohydrate, fat, as well as protein.

###### 

Diet and Physical Activities in Chinese NAFLD Patients With Moderate/Severe Versus Mild Hepatic Steatosis

  Characteristics                                                                              All                  Moderate/Severe Hepatic Steatosis (Liver HU ≤ 40)   Mild Hepatic Steatosis (Liver HU \> 40)   *P* Value
  -------------------------------------------------------------------------------------------- -------------------- --------------------------------------------------- ----------------------------------------- -----------
  Diet                                                                                                                                                                                                            
  Total calorie intake (kcal/day)                                                              1,527 (1237, 1911)   1,633 (1332, 2164)                                  1,456 (1178, 1797)                        **0.003**
  Total carbohydrate intake (g/day)                                                            210.2 (163, 262.4)   232.7 (181.1, 296.1)                                196.5 (152.9, 256.5)                      **0.016**
  Total fat intake (g/day)                                                                     49.5 (39.4, 67.2)    59.5 (42.2, 79.3)                                   45.2 (36.4, 63)                           **0.001**
  Total protein intake (g/day)                                                                 59.3 (48.4, 75.8)    64.6 (51.7, 81.7)                                   56.4 (43.9, 72.2)                         **0.037**
  Exercise                                                                                                                                                                                                        
  N                                                                                            160                  53                                                  107                                       
  Engaged in moderate work activity                                                            17 (10.6%)           8 (15.1%)                                           9 (8.4%)                                  0.197
  Total moderate work activity (minutes/week)[\*](#hep41435-note-0009){ref-type="fn"}          300 (225, 870)       780 (240, 1035)                                     300 (157.5, 570)                          0.321
  Engaged in transport activity                                                                110 (68.8%)          37 (69.8%)                                          73 (6.2%)                                 0.838
  Total transport activity (minutes/week)[†](#hep41435-note-0010){ref-type="fn"}               170 (100, 300)       150 (100, 280)                                      210 (95, 300)                             0.585
  Engaged in recreational activity                                                             70 (43.8%)           15 (28.3%)                                          55 (51.4%)                                **0.006**
  Total recreational activity (minutes/week)[†](#hep41435-note-0010){ref-type="fn"}            180 (90, 285)        180 (120, 240)                                      180 (90, 300)                             0.714
  Sum of all activity (minutes/week)[†](#hep41435-note-0010){ref-type="fn"}                    210 (60, 442.5)      160 (67.5, 405)                                     270 (60, 480)                             0.260
  Total physical activity meeting WHO recommendations[†](#hep41435-note-0010){ref-type="fn"}   98 (61.3%)           30 (56.6%)                                          68 (63.6%)                                0.396

Data are expressed as median (IQR) or n (%). Bold values have *P* Values \<0.05.

Only including participants who responded "yes" to that domain.

Including all participants (n = 160). Bold values have *P* Values \<0.05.

John Wiley & Sons, Ltd

Slightly more than half (61.3%) of the participants met WHO recommendations for physical activity, with no difference between patients with moderate/severe and those with mild steatosis (Table [3](#hep41435-tbl-0003){ref-type="table"}).

Median sum of all physical activity was 210 minutes per week, with no difference between patients with moderate/severe versus mild steatosis, but most activities were related to transport. Less than half (43.8%) of the patients participated in any recreation‐related activities, with a higher percentage among those with mild versus moderate/severe hepatic steatosis (51.4% vs. 28.3%).

Patients With Normal Versus Abnormal BMI {#hep41435-sec-0016}
----------------------------------------

Nineteen patients with normal BMI had moderate/severe hepatic steatosis. Their median age was 48 years (IQR 32‐63) and 42% were males. Compared to patients with moderate/severe steatosis and abnormal BMI, patients with moderate/severe steatosis and normal BMI had significantly smaller WC, lower HOMA‐IR, CAP (319 dB/m vs. 356.5 dB/m), and LFS (0.7 vs. 2.6) (*P* \< 0.005), but there were no significant differences in LSM, NAFLD‐FS and FIB‐4, or AST and ALT levels (Supporting Table [S1](#hep41435-sup-0001){ref-type="supplementary-material"}). Patients with moderate/severe hepatic steatosis and normal BMI also had smaller VFA, SFA, DMGA and DMGLDA (Supporting Table [S2](#hep41435-sup-0001){ref-type="supplementary-material"}), and lower median total calorie intake per day (1,396 kcal vs. 1,970 kcal) than those with moderate/severe steatosis and abnormal BMI. Although there were no differences in total physical activity, a higher proportion of patients with moderate/severe steatosis and normal BMI participated in recreational activity (47.4% vs. 17.6%) than those with abnormal BMI (Supporting Table [S3](#hep41435-sup-0001){ref-type="supplementary-material"}).

Ectopic Fat and Liver Fibrosis and Metabolic Syndrome {#hep41435-sec-0017}
-----------------------------------------------------

Liver fibrosis assessed by NAFLD‐FS had weak positive correlations with VFA (*r* = 0.223, *P* = 0.005), and with DMGLDA (*r* = 0.268, *P* = 0.001) and a strong negative correlation with DMGHU (*r* = −0.598, *P* \< 0.001). However, such correlations were not observed when liver fibrosis was assessed by LSM. We explored the correlation of the individual components of the NAFLD‐FS and VFA, VF HU, DMGLDA, and DMG HU. VFA and DMGLDA correlated best with BMI (*r* = 0.67, *P* \< 0.001; and *r* = 0.739, *P* \< 0.001) and AST/ALT ratio (*r* = −0.341, *P* \< 0.001; and *r* = −0.201, *P* = 0.011). VF HU did not correlate with any of the NAFLD‐FS components. DMG HU correlated with all of the individual components except for platelet and was significantly higher in those without compared to those with impaired fasting glycemia/diabetes (*P* \< 0.001).

Ninety patients met the criteria for MS. Compared with patients who did not meet the criteria for MS, those who had MS had more marked hepatic steatosis with median liver HU (42.6 vs. 51.3) (*P* \< 0.001). They also had larger VFA (181.1 cm^2^ vs. 121.9 cm^2^), SFA (165.8 cm^2^ vs. 119.8 cm^2^ ), as well as DMGLDA (10.4 cm^2^ vs. 7.8 cm^2^) (*P* \< 0.001).

Discussion {#hep41435-sec-0018}
==========

In this study, we applied analytic morphomics to study fat deposition in visceral, subcutaneous, and muscle compartments in 160 Chinese patients with NAFLD. We found that hepatic steatosis measured by CT scan HU correlated well with FibroScan CAP measurement and LFS. We also demonstrated that patients with moderate/severe hepatic steatosis had larger areas of fat in visceral, subcutaneous, and muscle compartments than those with mild hepatic steatosis. This was true in both patients with normal and those with abnormal BMI, and in men as well as women. Furthermore, we found that patients with moderate/severe steatosis had higher AST, ALT, and FibroScan LSM. As expected, patients with moderate/severe steatosis had higher BMI, WC, and prevalence of MS.

Various methods have been used to measure the quantity and quality of fat in liver, viscera, subcutaneous, and other body compartments. Although dual‐energy X‐Ray absorptiometry scans can provide information on total body composition, such as relative amounts of muscle, bone and fat, the measurements for subcutaneous fat versus visceral fat are extrapolated.[39](#hep41435-bib-0039){ref-type="ref"} Cross‐sectional imaging such as CT scan remain the gold standard and provide a convenient method to directly measure visceral versus subcutaneous fat. In combination with spatial measurements, CT scans can quantify not only visceral and subcutaneous fat but also fat in liver and muscle,[26](#hep41435-bib-0026){ref-type="ref"} and can also provide information on the quality of fat, which has been shown to have a stronger correlation with insulin resistance than subcutaneous or total body fat. Both magnetic resonance imaging and magnetic resonance spectroscopy provide robust measures of quantity as well as quality of adipose tissue depots, including liver and ectopic sites,[40](#hep41435-bib-0040){ref-type="ref"} but they are expensive and not widely available. In this study, we used CT scan and analytic morphomics, which allow us to provide precise and detailed measurements of fat in liver, visceral, subcutaneous, and other body compartments such as muscles. We have previously shown that analytic morphomics measurements are accurate predictors of new‐onset diabetes and survival after liver transplantation,[24](#hep41435-bib-0024){ref-type="ref"}, [27](#hep41435-bib-0027){ref-type="ref"} and provide important information about clinical outcomes in patients with liver disease.[25](#hep41435-bib-0025){ref-type="ref"}, [41](#hep41435-bib-0041){ref-type="ref"}, [42](#hep41435-bib-0042){ref-type="ref"}, [43](#hep41435-bib-0043){ref-type="ref"}

Several studies have shown that ectopic fat deposition in the liver, skeletal muscle, and heart is a key determinant of insulin resistance. Adipose tissue is not only a site for storage of lipids, but it also secretes various hormones and cytokines involved in regulating glucose and lipid metabolism and energy homeostasis. Studies using biopsies or magnetic resonance spectroscopy have implicated ectopic lipid accumulation in the pathogenesis of insulin resistance in muscle and liver and a role of muscle‐specific insulin resistance in promoting NAFLD.[44](#hep41435-bib-0044){ref-type="ref"} In healthy, young, lean persons, insulin resistance in skeletal muscle leads to diversion of ingested carbohydrate from muscle glycogen synthesis to the liver. This process, in combination with compensatory hyperinsulinemia, leads to increased hepatic *de novo* lipogenesis and increased hepatic triglyceride.[45](#hep41435-bib-0045){ref-type="ref"}

Studies in Japan and Korea also found a correlation between VFA measured by CT scans and the degree of fibrosis in patients with NAFLD. In a retrospective study of 324 NAFLD patients and 132 controls with no NAFLD in Korea, patients with NAFLD had higher gender‐adjusted VFA than controls, and multivariate regression analysis demonstrated that VFA was independently associated with significant fibrosis (F2‐F4) or NASH.[9](#hep41435-bib-0009){ref-type="ref"} Another study in 63 Japanese patients with biopsy‐proven NASH found that visceral fat volume measured by CT scans was greater in patients with advanced fibrosis versus those with mild fibrosis, but there was no correlation with the grade of steatohepatitis.[7](#hep41435-bib-0007){ref-type="ref"} In our study, only 5 patients had liver biopsies; thus, it was not possible to examine the association between VFA and grade of steatohepatitis or histological fibrosis stage. We did find a weak correlation between VFA and NAFLD‐FS, but no correlation with LSM. The reasons for the discordant result are unclear but likely related to the high proportion of patients with low LSM. Another reason might be that VFA correlated better with metabolic than liver components of NAFLD‐FS. Indeed, we found that VFA was significantly correlated with BMI and AST‐to‐ALT ratio, but not with platelet or albumin.

Fat in muscles had also been shown to be associated with NASH and hepatic fibrosis. One study in Japan found that patients with NASH had higher adipose tissue content in muscles as measured by CT scan than those with steatosis alone, and among those with NASH, intramuscular fat content was higher in those with stage 3 or 4 fibrosis than those with stage 1 or 2 fibrosis.[8](#hep41435-bib-0008){ref-type="ref"} In our study, fat in muscles correlated with NAFLD‐FS and FIB‐4. Very few studies have examined the correlation between fat in different body compartments and between ectopic fat and fat in liver. In one study of 105 middle‐age Japanese men with MS, VFA measured by CT scan correlated with CT HU of muscles and liver, but there were no correlations between CT HU of liver and CT HU of skeletal muscles.[4](#hep41435-bib-0004){ref-type="ref"} In our study, we found a significant correlation between VFA and fat in liver and muscles.

We found that while moderate/severe hepatic steatosis was more common in patients with abnormal BMI, 24% of patients with NAFLD and normal BMI also had moderate/severe hepatic steatosis. Compared to patients with normal BMI and mild steatosis, those with normal BMI and moderate/severe hepatic steatosis had larger VFA and also lower VFA HU in addition to higher BMI and higher prevalence of MS. Our findings highlight the importance of visceral fat in the pathogenesis of MS and NAFLD, particularly in patients with normal BMI. Many studies have shown that Asians with normal BMI are more prone to develop diabetes, MS, and NAFLD than other races.[46](#hep41435-bib-0046){ref-type="ref"}, [47](#hep41435-bib-0047){ref-type="ref"}, [48](#hep41435-bib-0048){ref-type="ref"} The exact reasons are unclear, although a higher prevalence of PNPLA3 I148M variant among Asians may contribute to increased risk of NAFLD, including those with normal BMI.[47](#hep41435-bib-0047){ref-type="ref"}, [49](#hep41435-bib-0049){ref-type="ref"}

As expected, we found that patients with moderate/severe hepatic steatosis had higher calorie intake than those with mild steatosis. We were surprised by the lack of physical activity, particularly recreational activity, not only among patients with moderate/severe steatosis but also those with mild steatosis. Although these data are limited by accuracy of self‐reporting, much effort is needed to promote recreational activity as China becomes more industrialized, with the shift from farming and blue collar jobs to sedentary white collar jobs and from moving around by cycling to buses, subway trains, and private cars.

The strengths of our study include a prospective design with detailed data on body composition, diet, and physical activity, but it also has some limitations. First, only 160 NAFLD patients were studied, which diminished the generalizability of our results. Second, histology was lacking in most patients. Third, diagnosis of NAFLD was based on historical imaging or histological results, and some patients may not have hepatic steatosis at the time of this study. We did exclude patients who had more than 5% weight loss during the interval between the qualifying test and enrollment into this study. Furthermore, 77% of patients had a FibroScan CAP score greater than 250 at enrollment. Fourth, we relied on self‐reporting for diet and physical activity, and the responses may not be accurate or complete.

In conclusion, we found that NAFLD patients with moderate/severe steatosis had more visceral and subcutaneous fat as well as more fat infiltration in muscle. They also had more liver damage and a higher prevalence of metabolic syndrome. These findings applied not only to patients with abnormal but also those with normal BMI. Our data support the benefits of reducing hepatic steatosis either through lifestyle interventions or medications. Our findings suggest major efforts are needed to promote physical activity in China to curb the growing epidemic of obesity, diabetes, and NAFLD.
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